17th Annual NATA Symposium

17th Annual NATA Symposium, Prague 2015The 17th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Royal Dublin Society in Dublin, Republic of Ireland, on April 14-15, 2016.

The preliminary scientific programme is now available. In agreement with this year’s theme, “From Theory to Praxis”, a special four-part session on perioperative patient blood management and its implementation has been scheduled on the first day, with the objective to provide clear take-home messages for clinical practice. On the second day, parallel sessions have been introduced.

The second announcement in PDF format can be downloaded here.

The deadline for abstract submission has been extended to January 17, 2016.
Click here for more information

Follow NATA on LinkedIn and Twitter

Join NATA's group on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

Slide Presentations from the 16th Annual NATA Symposium, Prague, 2015

We are pleased to provide NATA members with PDF versions of presentations delivered at past NATA symposia. These presentations are made available for NATA members with permission from the authors and may have been modified to remove unpublished or copyrighted material.

To access presentations from the 16th Annual NATA Symposium, which was held in Prague on April 16-17, 2015, please log-in and go to the "Members' Area" section or click on the link below.
Slide Presentations from the 16th Annual NATA Symposium

News

European Medicines Agency's Committee for Medicinal Products for Human Use recommends marketing authorisation for idarucizumab (Praxbind), a specific reversal agent for dabigatran

On 24 September 2015, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Praxbind, a specific reversal agent for dabigatran, intended for use when rapid reversal of the anticoagulant effects of Pradaxa (dabigatran etexilate) is required inadult patients.

The full indication is: “Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:
• For emergency surgery/urgent procedures
• In life-threatening or uncontrolled bleeding."
Read more on this

From the Literature

Feb 12, 2016

Published: Dec 2015

Siegal DM, Curnutte JT, Connolly SJ, et al.

Andexanet alfa for the reversal of factor Xa inhibitor activity.
N Engl J Med 2015;373:2413-2424

#

NATA REVIEW:
The direct factor Xa inhibitors apixaban and rivaroxaban are increasingly used for the prevention and the...
REVIEW by:
D. Faraoni

Published: Dec 2015

Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al.

Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial.
JAMA 2015;314:2514-2523.

#

NATA REVIEW:
Over the past few years, the "age of blood" has been one of the hot topics discussed regularly during meetings...
REVIEW by:
J. Meier

Published: Dec 2015

Ding YY, Kader B, Christiansen CL, Berlowitz DR

Hemoglobin level and hospital mortality among ICU patients with cardiac disease who received transfusions.
J Am Coll Cardiol 2015;66:2510-2518.

#

NATA REVIEW:
This is an interesting investigation which serves to better inform healthcare providers in their clinical decision-making...
REVIEW by:
C. G. Koch

Published: Nov 2015

Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ, Jr., Sarode R

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.
Transfusion 2015;55:2722-2729.

#

NATA REVIEW:
Immediate reversal of the anticoagulant effect of vitamin K antagonists can be achieved by administration of...
REVIEW by:
M. Levi

Published: Oct 2015

Young P, Bailey M, Beasley R, et al.

Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial.
JAMA 2015;314:1701-1710.

#

NATA REVIEW:
The SPLIT study, a double-bind, cluster randomised, double-crossover trial that was conducted in 4 ICUs...
REVIEW by:
M. Piagnerelli

Published: Oct 2015

Sowers N, Froese PC, Erdogan M, Green RS

Impact of the age of stored blood on trauma patient mortality: a systematic review.
Can J Surg 2015;58:335-342.

#

NATA REVIEW:
In this systematic review, Sowers et al. investigated the impact of the age of stored red blood cells...
REVIEW by:
S. R. Ostrowski